Unknown

Dataset Information

0

Pomalidomide combinations are a safe and effective option after daratumumab failure.


ABSTRACT:

Purpose

Outcomes of multiple myeloma (MM) patients who are refractory to daratumumab are dismal and no standard of treatment exists for this patients' population. Here, we investigate the role of pomalidomide combinations in daratumumab-refractory MM patients.

Methods

We performed a retrospective analysis of myeloma patients treated at four referral centers (three in Germany and one in Italy). Review chart identified 30 patients with relapsed and refractory myeloma, who progressed during treatment with daratumumab and were treated with pomalidomide-based combinations in the subsequent lines of therapy.

Results

Responses improved from 37% with daratumumab to 53% with pomalidomide. Of seven patients with extramedullary MM (EMM), four achieved a clinical stabilization with pomalidomide, including one patient with a long-lasting complete response. Median progression-free survival and overall survival were 6 and 12 months, respectively. Pomalidomide combinations were well tolerated, no patient discontinued treatment due to adverse events.

Conclusion

These data show that pomalidomide-based combinations can be an effective and safe salvage regimen for daratumumab-refractory patients, including those with EMM.

SUBMITTER: Brioli A 

PROVIDER: S-EPMC10356885 | biostudies-literature | 2023 Aug

REPOSITORIES: biostudies-literature

altmetric image

Publications

Pomalidomide combinations are a safe and effective option after daratumumab failure.

Brioli Annamaria A   Gengenbach Laura L   Mancuso Katia K   Binder Mascha M   Ernst Thomas T   Heidel Florian H FH   Stauch Thomas T   Zamagni Elena E   Hilgendorf Inken I   Hochhaus Andreas A   Engelhardt Monika M   von Lilienfeld-Toal Marie M  

Journal of cancer research and clinical oncology 20230213 9


<h4>Purpose</h4>Outcomes of multiple myeloma (MM) patients who are refractory to daratumumab are dismal and no standard of treatment exists for this patients' population. Here, we investigate the role of pomalidomide combinations in daratumumab-refractory MM patients.<h4>Methods</h4>We performed a retrospective analysis of myeloma patients treated at four referral centers (three in Germany and one in Italy). Review chart identified 30 patients with relapsed and refractory myeloma, who progressed  ...[more]

Similar Datasets

| S-EPMC1727187 | biostudies-other
| S-EPMC11467276 | biostudies-literature
| S-EPMC6167235 | biostudies-other
| S-EPMC7685974 | biostudies-literature
| S-EPMC5570682 | biostudies-literature
| S-EPMC5570044 | biostudies-literature
| S-EPMC9640701 | biostudies-literature
| S-EPMC9458897 | biostudies-literature
| S-EPMC8497198 | biostudies-literature